72402-14-3

Basic information

• Product Name: Methyl-2,3-O-isopropylidene-D-ribofuranoside
• Synonyms: METHYL 2,3-O-ISOPROPYLIDENE-D-RIBOFURANOSIDE;METHYL 2,3-O-ISOPROPYLIDEN-D-RIBOFURANOSE;METHYL-2,3-O-ISOPROPYLIDENE-ALPHA,BETA-D-RIBOFURANOSIDE;METHYL 2,3-O-ISOPROPYLIDENE-B-D-RIBOFURANOSIDE;[(3aR,4R,6aR)-6-methoxy-2,2-dimethyl-tetrahydro-2H-furo[3,4-d][1,3]dioxol-4-yl]methanol;((3aR,4R,6aR)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol
• CAS NO: 72402-14-3
• Molecular Formula: C₉H₁₆O₅
• Molecular Weight: 204.22
• Mol File: 72402-14-3.mol
• Article Data: 45

Chemical Properties

• Boiling Point: 72-75 °C(Press: 0.6 Torr)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.14±0.10(Predicted)
• CAS DataBase Reference: Methyl-2,3-O-isopropylidene-D-ribofuranoside(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-2,3-O-isopropylidene-D-ribofuranoside(72402-14-3)
• EPA Substance Registry System: Methyl-2,3-O-isopropylidene-D-ribofuranoside(72402-14-3)

Safety Data

• Hazardous Substances Data: 72402-14-3(Hazardous Substances Data)

Usage

Uses

Methyl 2,3-O-Isopropylidene-D-ribofuranoside can be prepared to use as PRMT5 inhibitors.

Upstream product

• 67-56-1 methanol 
• 532-20-7 D-Ribose 
• 77-76-9 2,2-dimethoxy-propane 
• 144732-43-4 (3aR,6R,6aR)-4-Methoxy-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxole 
• 50-69-1 D-ribose 
• 67-64-1 acetone 
• 10257-32-6 D-ribose 
• 36468-53-8 β-D-ribofuranose 
• 122-51-0 orthoformic acid triethyl ester 
• 1824-96-0 methyl ribofuranoside 

Downstream Products

• 72402-15-4 1-O-methyl-5-O-benzyl-2,3-O-isopropylidene-D-ribofuranoside 
• 115509-13-2 (3aR,6aR)-2,2-Dimethyl-3a,6a-dihydro-cyclopenta[1,3]dioxol-4-one 
• 595581-64-9 (3aR,6aR)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-one 
• 144993-84-0 methyl 5,6-didehydro-5,6-dideoxy-2,3-O-isopropylidene-D-allofuranoside 
• 155855-53-1 (3aR,4S,6R,6aS)-6-(benzylamino)-2,2-dimethyltetrahydro-3ah-cyclopenta-[d][1,3]-dioxol-4-ol 
• 1444301-50-1 (3aS,4R,6S,6aR)-N-benzyl-6-(2-(benzyloxy)ethoxy)-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-amine 
• 1444301-53-4 (3aS,4R,6S,6aR)-N-benzyl-6-((2-tert-butoxy)ethoxy)-2,2-dimethyl-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-amine 
• 1444301-59-0 (1S,2S,3R,5S)-3-(benzylamino)-5-(2-(benzyloxy)ethoxy)cyclopentane-1,2-diol 
• 1402150-32-6 (1S 2S,3R,5S)-3-[(5-amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol 
• 1354945-69-9 9-[(1’R,2’S,3’S,4’S)-2’,3’-dihydroxyl-4'-hydroxyethoxycyclopenta-1'-yl]-9H-2-thiopropyl-6-chloro-8-azepine 
• 114817-96-8 (4S,5R)-2,2-dimethyl-4-hydroxymethyl-5-vinyl-1,3-dioxolane 
• 869476-97-1 (3aS,6aS)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-one 
• 683276-44-0 (4R,5S)-4,5-O-isopropylidenecyclopenten-1-ol 
• 87-72-9 L-arabinofuranose 

Relevant articles and documents

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Tumor immunity compound and application thereof

Disclosed are a tumor immunity compound and an application thereof. The invention discloses a compound as shown in the formula (I), optical isomers thereof, and pharmaceutically acceptable salts thereof, and an application of the compound as an STING agonist.

Total Synthesis of Meayamycin and O-Acyl Analogues

A short, scalable total synthesis of meayamycin is described by an approach that entails a longest linear sequence of 12 steps (22 steps overall) from commercially available chiral pool materials (ethyl l-lactate, BocNH-Thr-OH, and d-ribose) and introduces the most straightforward preparation of the right-hand subunit detailed to date. The use of the approach in the divergent synthesis of a representative series of O-acyl analogues is exemplified.